The PARP-1 inhibitors can selectively kill the cancer cells with homologous recombination (HR) defect caused by BRCA1/2 mutations, and have been approved for the therapy of cancers such as ovarian cancer, prostate cancer and breast cancer, etc (Rouleau et al., 2010; Lin and Kraus, 2017; Lord and Ashworth, 2017). Here, BRCA1 is linked to cancer.